Citadel Advisors
ANIX icon

Citadel Advisors’s Anixa Biosciences ANIX Stock Holding History

Citadel Advisors’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,100
Closed -$39.9K – 12690
2025
Q2 		$39.9K Sell
12,100
-11,300
-48% -$32.3K ﹤0.01% 11884
2025
Q1 		$66.9K Buy
23,400
+6,700
+40% +$19.2K ﹤0.01% 11975
2024
Q4 		$38.7K Buy
16,700
+10,000
+149% +$31.1K ﹤0.01% 12639
2024
Q3 		$21.1K Buy
+6,700
New +$20.6K ﹤0.01% 12736
2024
Q2 		– Sell
-4,100
Closed -$12.8K – 14177
2024
Q1 		$12.8K Sell
4,100
-16,600
-80% -$66.2K ﹤0.01% 13342
2023
Q4 		$80.3K Buy
20,700
+20,400
+6,800% +$68.8K ﹤0.01% 11223
2023
Q3 		$981 Sell
300
-900
-75% -$3.15K ﹤0.01% 13938
2023
Q2 		$3.84K Sell
1,200
-6,200
-84% -$23.9K ﹤0.01% 13653
2023
Q1 		$31.8K Buy
7,400
+1,500
+25% +$6.57K ﹤0.01% 12671
2022
Q4 		$25.1K Buy
+5,900
New +$28.4K ﹤0.01% 12939
2022
Q1 		– Sell
-11,500
Closed -$34K – 13502
2021
Q4 		$34K Sell
11,500
-15,400
-57% -$62.3K ﹤0.01% 13421
2021
Q3 		$128K Buy
26,900
+11,700
+77% +$52.8K ﹤0.01% 12571
2021
Q2 		$59K Buy
+15,200
New +$64.7K ﹤0.01% 13257

Other funds holding ANIX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors's ANIX Position: Q1 2026 in Review

Citadel Advisors sold out of Anixa Biosciences (ANIX) in Q1 2026, closing a stake of 29,692 shares — an estimated $87.9K sold.

Citadel Advisors first reported a position in ANIX in Q4 2020 and held it in 17 quarters. The position peaked at $317K in Q3 2025. 60 funds tracked by Wall St. Rank hold ANIX as of Q1 2026.

  • Citadel Advisors reported no remaining Anixa Biosciences position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 29,692 Anixa Biosciences shares in Q1 2026, an estimated $87.9K.
  • Citadel Advisors first reported a position in Anixa Biosciences in Q4 2020 and held it in 17 quarters.
  • Citadel Advisors's Anixa Biosciences position peaked at $317K in Q3 2025.
  • 60 funds tracked by Wall St. Rank held Anixa Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.